Venatorx Pharmaceuticals, Inc.

The US Food and Drug Administration approvals of Day One Biopharmaceuticals, LLC ’s Ojemda (tovorafenib) and ImmunityBio Inc. ’s Anktiva (nogapendekin alfa inbakicept-pmln) last week provided a boos

The sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producin

The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals. The number of us

Amid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of